Onconetix
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
Nov 12Expected
Q1 2024
Next
-33,282.4
-22,521.26
-11,760.13
-999
Expected EPS
N/A
Actual EPS
N/A
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Show More
CEO
David Allan White
Employees
2
Country
United States
ISIN
US68237Q5009
WKN
000A42RJ8
Listings
0 Comments
Share your thoughts
FAQs
What is Onconetix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Onconetix stocks are traded under the ticker J4T2.F.
When is the next Onconetix earnings date?▼
Onconetix is going to release the next earnings report on November 12, 2026.
How many employees does Onconetix have?▼
As of November 8, 2026, the company has 2 employees.
In which sector is Onconetix located?▼
Onconetix operates in the Health & Wellness sector.
When did Onconetix complete a stock split?▼
Onconetix has not had any recent stock splits.
Where is Onconetix headquartered?▼
Onconetix is headquartered in CINCINNATI, United States.